Special Issue

Therapeutic Potential for Cannabinoid and Its Receptor

Message from the Guest Editors

Cannabinoid compounds, occurring in cannabis, produce their effects via interaction with the brain's endocannabinoid system (ECS). The ECS, through the cannabinoid type 1 (CB1) and type 2 (CB2) receptors, is involved in many emotional functions and there are a wide variety of interactions between the CB receptors and many different neurotransmitters and neuromodulators in the central and peripheral nervous system. The pharmacological modulation of ECS functions could be useful for the treatment of various medical conditions. However, the knowledge on the potential mechanisms of cannabinoid activities still requires further enrichment. Thus, the aim of the Special Issue is to expand the current knowledge of the role of the ECS in the pathomechanisms of many mental and physical dysfunctions. This knowledge may in the future open up new possibilities for the development of cannabinoid-based therapies for many disorders. Therefore, I invite you to participate with either an original article or a review focused on some aspects of the subject.

Guest Editors

Dr. Marta Kruk-Słomka

Dr. Jolanta Orzelska-Górka

Dr. Ewa Kędzierska

Dr. Ewa Gibuła-Tarłowska

Deadline for manuscript submissions

closed (25 February 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/164302

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

